As of Jun 28
| +0.27 / +5.08%|
The 2 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 14.00, with a high estimate of 21.00 and a low estimate of 7.00. The median estimate represents a +150.90% increase from the last price of 5.58.
The current consensus among 6 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.